The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of
all lung cancer cases. In spite of achievements in understanding the pathogenesis of this …

Lung cancer is currently the leading cause of cancer-related death in worldwide, non-small
cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Surgery, platinum …

Immunosuppression of tumour-infiltrating lymphocytes (TIL) is a common feature of
advanced cancer, but its biological basis has remained obscure. We demonstrate here a …

Abstract Background Immune-checkpoint inhibitors (ICIs) changed the therapeutic
landscape of patients with lung cancer. However, only a subset of them derived clinical …

Abstract Treatment of lung cancer remains a challenge, and lung cancer is still the leading
cause of cancer‐related mortality. Immunotherapy has previously failed in lung cancer but …

In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab,
durvalumab, and avelumab, were approved by the FDA for the treatment of multiple …

Abstract Background: Tumor-infiltrating lymphocytes (TILs) are usually measured using
subjective methods. Studies suggest that TIL subtypes have independent roles in cancer …

Blockade of the protein–protein interaction between the transmembrane protein
programmed cell death protein 1 (PD‐1) and its ligand PD‐L1 has emerged as a promising …

Therapeutic antibodies to programmed death receptor 1 (PD-1) and its ligand PD-L1 show
promising clinical results. Anti-PD-L1 immunohistochemistry (IHC) may be a biomarker to …

Background Immunotherapeutic approaches to treating cancer have been evaluated during
the last few decades with limited success. An understanding of the checkpoint signaling …